|0.9100||-0.0201||-2.16%||Vol 8.54K||1Y Perf -64.77%|
|Oct 4th, 2023 15:02 DELAYED|
|0.06 6.43%||- -|
|Target Price||7.30||Analyst Rating||Hold 3.00|
|Potential %||702.20||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★ 47.25|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★+ 47.24|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||1.32||Earnings Rating||—|
|Market Cap||93.41M||Earnings Date||21st Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||21st Nov 2023|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||18.15K|
|Avg. Monthly Volume||83.71K|
|Avg. Quarterly Volume||64.23K|
Burning Rock Biotech Limited (NASDAQ: BNR) stock closed at 0.9301 per share at the end of the most recent trading day (a -5.09% change compared to the prior day closing price) with a volume of 10.03K shares and market capitalization of 93.41M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 753 people. Burning Rock Biotech Limited CEO is Yusheng Han.
The one-year performance of Burning Rock Biotech Limited stock is -64.77%, while year-to-date (YTD) performance is -58.66%. BNR stock has a five-year performance of %. Its 52-week range is between 0.871349 and 3.8, which gives BNR stock a 52-week price range ratio of 1.32%
Burning Rock Biotech Limited currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 1.67, a price-to-sale (PS) ratio of 3.96, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -45.63%, a ROC of -57.56% and a ROE of -56.30%. The company’s profit margin is -97.54%, its EBITDA margin is -178.60%, and its revenue ttm is $59.16 Million , which makes it $0.67 revenue per share.
Of the last four earnings reports from Burning Rock Biotech Limited, there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Burning Rock Biotech Limited’s next earnings report date is 21st Nov 2023.
The consensus rating of Wall Street analysts for Burning Rock Biotech Limited is Hold (3), with a target price of $7.3, which is +702.20% compared to the current price. The earnings rating for Burning Rock Biotech Limited stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Burning Rock Biotech Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Burning Rock Biotech Limited has a Sell technical analysis rating based on Technical Indicators (ADX : 21.65, ATR14 : 0.10, CCI20 : -62.75, Chaikin Money Flow : -0.05, MACD : -0.12, Money Flow Index : 43.46, ROC : -6.99, RSI : 33.92, STOCH (14,3) : 25.14, STOCH RSI : 0.56, UO : 27.09, Williams %R : -74.86), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Burning Rock Biotech Limited in the last 12-months were:
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.